Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Director Michael Douglas Taylor sold 22,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $40.77, for a total value of $917,325.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
DCPH opened at $36.30 on Friday. The business has a 50 day moving average price of $23.11 and a 200 day moving average price of $24.33. Deciphera Pharmaceuticals Inc has a twelve month low of $18.55 and a twelve month high of $42.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. The firm has a market cap of $762.39 million, a P/E ratio of -12.87 and a beta of 2.34.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.12) by $0.56. The company had revenue of $25.00 million during the quarter, compared to analyst estimates of $20.00 million. As a group, analysts anticipate that Deciphera Pharmaceuticals Inc will post -4.29 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP acquired a new stake in Deciphera Pharmaceuticals in the 4th quarter worth approximately $4,337,000. Geode Capital Management LLC lifted its holdings in shares of Deciphera Pharmaceuticals by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 166,904 shares of the company’s stock worth $3,503,000 after buying an additional 27,157 shares during the last quarter. Norges Bank acquired a new position in shares of Deciphera Pharmaceuticals during the fourth quarter worth approximately $6,974,000. Marshall Wace North America L.P. lifted its holdings in shares of Deciphera Pharmaceuticals by 4,025.4% during the first quarter. Marshall Wace North America L.P. now owns 57,714 shares of the company’s stock worth $1,340,000 after buying an additional 56,315 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Deciphera Pharmaceuticals by 1,506.1% during the fourth quarter. Bank of America Corp DE now owns 23,561 shares of the company’s stock worth $494,000 after buying an additional 22,094 shares during the last quarter. Hedge funds and other institutional investors own 59.10% of the company’s stock.
DCPH has been the subject of several recent research reports. Guggenheim boosted their price target on Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday. Leerink Swann restated a “positive” rating and issued a $29.00 target price (up from $20.00) on shares of Deciphera Pharmaceuticals in a report on Wednesday. Zacks Investment Research upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $26.00 target price for the company in a report on Monday, August 5th. SunTrust Banks boosted their target price on Deciphera Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Piper Jaffray Companies boosted their target price on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, June 3rd. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $47.90.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Article: Using other technical indicators with support levels
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.